Pharmaceutical

SNK-396 by Synerk for Lipid Disorders: Likelihood of Approval

SNK-396is under clinical development by Synerk and currently in Phase I for Lipid Disorders.

Jul 1, 2023 - 20:00
SNK-396is under clinical development by Synerk and currently in Phase I for Lipid Disorders.
Read the original article

Tags:

Previous Article

IN-14199 by HK inno.N for Constipation: Likelihood of Approval

Next Article

Immune Thrombocytopenia by NovelMed Therapeutics for Idiopathic Thrombocytopenic...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 by Huahui Health for Hepatitis D: Likelihood of ...

Jan 9, 2024

Watch: What is in utero gene editing?

Watch: What is in utero gene editing?

Feb 21, 2024

Gliosarcoma drugs in development, 2023

Nov 30, 2023